Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
group a meningococcal polysaccharide vaccine
- Development stage
- Phase 3
- Lead developer
- Institut Mérieux
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The group A meningococcal polysaccharide vaccine is a vaccine composed of purified capsular polysaccharides derived from *Neisseria meningitidis* serogroup A. It functions by stimulating the body's immune system to produce specific antibodies against the serogroup A capsule, thereby conferring protection against invasive meningococcal disease, particularly meningococcal meningitis, caused by this specific serogroup. As a T-cell independent immunogen, it induces an immune response without T-cell involvement and typically does not generate immunological memory.
- Other names
- Group A Meningococcal Polysaccharide VaccineMeningococcal Polysaccharide Vaccine Serogroup A
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)
Beyond the preview
Go deeper on group a meningococcal polysaccharide vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on group a meningococcal polysaccharide vaccine.